Neurological Complications of Measles Virus Infection

Wild-Type Measles Neurological Manifestations

Wild-type measles causes encephalitis in approximately 1 per 1,000 infected persons, presenting with fever, altered mental status, seizures, and potential permanent CNS impairment, according to the Centers for Disease Control and Prevention (CDC) 1, 2
The case fatality rate for measles in the United States is 1-2 per 1,000 cases, with permanent brain damage possible in survivors of encephalitis 2
Symptoms of encephalitis typically appear during or shortly after the acute measles illness, with onset of neurological signs occurring around 10 days after initial infection 3

Subacute Sclerosing Panencephalitis (SSPE)

SSPE is a rare but invariably fatal late complication appearing years after the initial measles infection, caused by persistent mutant measles virus in the CNS, with a risk of approximately 4-11 per 100,000 measles-infected individuals, particularly those infected at young ages, as stated by the American Academy of Pediatrics 2, 4, 5
Clinical presentation of SSPE includes insidious personality changes, intellectual decline progressing to dementia, myoclonic jerks with characteristic 1:1 EEG periodic complexes, motor deterioration, coma, and death 5

Vaccine-Strain Measles Neurological Events

Encephalopathy after MMR vaccination occurs at approximately 1 case per 2 million doses distributed, vastly lower than the 1 per 1,000 risk with wild-type measles, according to the CDC 3, 6
The CDC and the Advisory Committee on Immunization Practices (ACIP) definitively state that MMR vaccine does not increase SSPE risk 1, 2, 5
Measles vaccination has essentially eliminated SSPE in countries with high vaccination coverage, as reported by the World Health Organization 2

Clinical Algorithm for Recognition

Monitor for fever, altered mental status, seizures, or focal neurological signs during or shortly after measles illness, and consider SSPE in any patient with progressive neurological deterioration and history of measles infection, as recommended by the American Academy of Neurology 1, 2, 3, 4, 5
Obtain CSF for measles-specific antibody testing showing intrathecal synthesis to diagnose SSPE 5

Treatment Considerations

Vitamin A supplementation is recommended for children with measles, with 100,000 IU for children <12 months and 200,000 IU for children ≥12 months, as suggested by the World Health Organization 2
Supportive care with treatment of secondary bacterial infections is essential for acute measles management, according to the CDC 2
Intrathecal ribavirin has been attempted with limited success for SSPE treatment, as reported by the National Institutes of Health 5

Management of Suspected CNS Involvement Following MMR Vaccination

Clinical Presentation and Management

If true CNS involvement from MMR vaccine-strain measles virus occurred, acute neurological manifestations would be observed within 6-15 days post-vaccination, and management focuses on supportive care, with an incidence of approximately 1 case per 2 million doses, according to the Centers for Disease Control and Prevention 7, 8
Neurological signs, such as fever, altered mental status, seizures, behavioral changes, or altered consciousness, appear with a statistically significant non-random distribution on days 8-9 after MMR administration, as reported by the Centers for Disease Control and Prevention 7, 8
The American Academy of Pediatrics recommends managing fever aggressively with acetaminophen or ibuprofen and controlling seizures with standard anticonvulsant protocols, as outlined in the MMWR Recommendations and Reports 7, 8
The Centers for Disease Control and Prevention advises reporting all suspected serious adverse events following MMR vaccination to the Vaccine Adverse Event Reporting System (VAERS) for passive surveillance 7, 8

Risk Stratification and Prognosis

Children with personal or family history of seizures have minimally increased risk for febrile seizures (not encephalopathy) after MMR, but this does not contraindicate vaccination, as stated by the Centers for Disease Control and Prevention 7, 8
Febrile seizures following MMR carry no increased risk for subsequent epilepsy compared to febrile seizures from other causes, according to the MMWR Recommendations and Reports 8

Neurological Manifestations of MMR Vaccine

Clinical Presentation

The Centers for Disease Control and Prevention recommends monitoring for fever onset beginning 5-12 days after vaccination, as fever is often the initial manifestation, typically presenting with a temperature of 103°F (39.4°C) or higher 9, 10, 11
The American Academy of Pediatrics suggests assessing for neurological signs, including altered mental status, seizures, and behavioral changes, which may occur in conjunction with fever 9, 10, 11

Risk Context and Comparative Safety

The Advisory Committee on Immunization Practices acknowledges that the incidence of encephalitis or encephalopathy after measles vaccination is lower than the observed incidence of encephalitis of unknown etiology in the general population 9, 10, 11

Special Populations

The Centers for Disease Control and Prevention states that children with a personal or family history of seizures have a minimally increased risk for febrile seizures after MMR, but this does not contraindicate vaccination, as the benefits outweigh the risks 9, 10, 11

Treatment Approach

The American Academy of Pediatrics recommends continuing anticonvulsants in children already on therapy, as prophylactic anticonvulsants are not feasible for prevention 9, 10, 11

Measles Encephalitis Burden and Prevention

Historical Disease Burden

Approximately 3.5 million measles cases occurred annually in the United States before 1963, representing essentially an entire birth cohort as virtually all children acquired measles 12, 13, 14
Encephalitis occurred in approximately 1 per 1,000 reported measles cases, meaning the rate was consistent across the disease spectrum 12, 13, 14
With 3.5 million annual cases and a 1:1,000 encephalitis rate, this translates to approximately 3,500 cases of measles encephalitis per year in children before vaccine introduction 12, 13, 14

Clinical Consequences of Measles Encephalitis

Survivors of measles encephalitis often had permanent brain damage and mental retardation, making this a devastating complication beyond the acute illness 12, 13, 14
Encephalitis was one of the two most common causes of death from measles, along with pneumonia, contributing to the overall case-fatality rate of 1-2 per 1,000 cases 12, 13, 14

Impact of Vaccination

Measles vaccination has essentially eliminated SSPE from the United States in countries with high vaccination coverage 12, 13, 14
The reported incidence of measles decreased by greater than 99% following widespread vaccination programs 12, 13, 14

Neurologic Reactions from MMR Vaccine

Clinical Considerations

Neurologic symptoms beyond 30 days post-vaccination are not attributable to the vaccine, according to the MMWR Recommendations and Reports 15
Aseptic meningitis is not associated with the Jeryl Lynn mumps strain used in the United States, as stated in the MMWR Recommendations and Reports 15

Management of Seizures Following Vaccination in Patients with Seizure Disorders

Immediate Post-Vaccination Seizure Management

The Centers for Disease Control and Prevention recommends that children with a history of seizure disorders who experience seizures after vaccination should continue their current anticonvulsant medications, receive appropriate fever management, and proceed with future vaccinations as scheduled, since vaccine-associated seizures do not cause permanent neurological damage or increase the risk of developing epilepsy 16, 17
The American Academy of Pediatrics suggests treating seizures with standard anticonvulsant protocols while managing fever aggressively with acetaminophen or ibuprofen, and continuing existing anticonvulsant medications without interruption 16, 18

Risk Stratification and Future Vaccination Decisions

The Advisory Committee on Immunization Practices explicitly concluded that children with seizure histories should be vaccinated just as children without such histories, as the benefits greatly outweigh the minimal increased risk of febrile seizures 16, 17
The Centers for Disease Control and Prevention recommends documenting in the medical record that the small risk of post-immunization seizures and benefits of vaccination have been discussed with parents 16, 17

Special Considerations for Unstable Neurological Conditions

For infants with active, evolving neurological disorders, the Centers for Disease Control and Prevention recommends delaying DTP vaccination until the condition is stabilized and treatment regimen established 18

Documentation Requirements

The American Academy of Pediatrics recommends documenting that parents have been advised of the small increased risk of seizures following vaccination, providing specific instructions on what to do if a seizure occurs, and recording that the benefits of vaccination have been discussed and outweigh the minimal seizure risk 16, 17